Anti-Lewis Y [C14]
Invented at University of Nottingham
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153394 |
| Applications | ELISA FACS IHC |
| Antigen/Gene or Protein Targets | Lewis Y |
| Reactivity | Human |
| Relevance | MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are functional glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate. |
| Host | Mouse |
| Immunogen | Tumor cells |
| Subclass | IgG |
| Strain | Balb/c |
| Research Area | Cancer, Epigenetics & Nuclear Signalling |
References: 2 entries
Durrant et al. 1989. J Natl Cancer Inst. 81(9):688-96. PMID: 2468779.
Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer.
Europe PMC ID: 2468779
Add a reference
References: 2 entries
Durrant et al. 1989. J Natl Cancer Inst. 81(9):688-96. PMID: 2468779.
Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer.
Add a reference
